doi: 10.18632/oncotarget.11267 128 ArnoldussenIACWiesmannMPelgrimCEWielemakerEMvan DuyvenvoordeWAmaral-SantosPLet al
Really I cant say thank you enough. Jeff Blume 01/30/2020 Great product Prompt shipping and I love this product for my copd
Key components include resistance training and daily moderate aerobic exercise, adequate high-quality protein intake (1.21.6 g/kg adjusted body weight/day) distributed evenly across meals, micronutrient supplementation, and periodic reassessment of lean mass via DXA, BIA or functional outcomes (e.g., handgrip strength and gait speed) to optimize fat loss while minimizing sarcopenia risk (Table 2)
FDA-Approved Clinical Indications Primary Indication Management of Resistant Anemia and Muscle Cramps: Specifically indicated for the treatment of carnitine deficiency in dialysis patients to improve the response to Erythropoiesis-Stimulating Agents (ESAs) in cases of resistant anemia and to reduce the frequency and severity of intradialytic skeletal muscle cramps
Phase 3 trials currently underway Seven TRIUMPH trials are testing retatrutide across multiple indications: TRIUMPH-1 : Obesity without diabetes TRIUMPH-2 : Type 2 diabetes TRIUMPH-3 : Obesity with type 2 diabetes TRIUMPH-4 : Obesity with knee osteoarthritis (COMPLETED, 28.7% weight loss) TRIUMPH-5 : Obstructive sleep apnea TRIUMPH-6 and 7 : Additional indications These trials will provide the definitive data for the commercial dosage chart
